LEADER 04037nam 22006375 450 001 9910751396403321 005 20231012193305.0 010 $a9783031328152 024 7 $a10.1007/978-3-031-32815-2 035 $a(MiAaPQ)EBC30786184 035 $a(CKB)28495740800041 035 $a(Au-PeEL)EBL30786184 035 $a(DE-He213)978-3-031-32815-2 035 $a(PPN)272915319 035 $a(EXLCZ)9928495740800041 100 $a20231012d2023 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBiomarkers for Huntington's Disease $eImproving Clinical Outcomes /$fedited by Elizabeth A. Thomas, Georgia M. Parkin 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (476 pages) 225 1 $aContemporary Clinical Neuroscience,$x2627-5341 311 $a9783031328145 327 $aMolecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers -- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics -- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers -- MRI - non-invasive functional MRI measures -- The evolution of clinical trial methodology.-Digital biomarkers -- The future of telehealth -- Summary and future trends. 330 $aHuntington?s disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important. 410 0$aContemporary Clinical Neuroscience,$x2627-5341 606 $aNeurosciences 606 $aNeurology 606 $aNeurophysiology 606 $aNeuropharmacology 606 $aNeuroscience 606 $aNeurology 606 $aNeurophysiology 606 $aNeuropharmacology 615 0$aNeurosciences. 615 0$aNeurology. 615 0$aNeurophysiology. 615 0$aNeuropharmacology. 615 14$aNeuroscience. 615 24$aNeurology. 615 24$aNeurophysiology. 615 24$aNeuropharmacology. 676 $a616.851 676 $a616.851 700 $aThomas$b Elizabeth A$01432938 701 $aParkin$b Georgia M$01432939 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 912 $a9910751396403321 996 $aBiomarkers for Huntington's Disease$93578001 997 $aUNINA